September 24, 2021 06:22 AM EDTUpdated 05:37 PM

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

→ Another CEO opportunity has presented itself for James Scibetta, the chief executive of Maverick Therapeutics when Takeda ponied up $525 million in March …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech

Alex Hoffman

Senior Editor

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

With Mav­er­ick now in Takeda's hands, James Sci­bet­ta turns the page; Roivant CMO leaves in fa­vor of small IL-2 biotech

Senior Editor

Editor

Sign up to read this article for free.

With Maverick now in Takeda's hands, James Scibetta turns the page; Roivant CMO leaves in favor of small IL-2 biotech